Market Overview

UPDATE: Stifel Nicolaus Raises PT to $38 on Align Technology on Trial Outlook

Share:
Related ALGN
Thursday's After-Hours Movers: Amazon, Google, Starbucks And More
Benzinga's Top Upgrades
Healthcare stock screen of the month: CF growth > EPS growth, fat AT margin (Seeking Alpha)

Stifel Nicolaus reiterated its Buy rating on Align Technology (NASDAQ: ALGN) and raised the price target from $32.00 to $38.00.

Stifel Nicolaus said, "Align's patent infringement trial against ClearCorrect is scheduled to begin today. … With the limited information contained in the public filings, Mr. Lavelle acknowledged it would be difficult to handicap the potential outcome of the trial. That said, he seems to think Align has a strong position, given the broad claims covered by the seven patents being asserted against ClearCorrect as well as Align's prior success with some of these same patents in prior litigation with OrthoClear. Additionally, two of the seven patents were recently re-validated by the United States Patent and Trademark Office (USPTO), which likely mitigates ClearCorrect's ability to claim the patents are invalid."

Align Technology closed at $31.90 on Friday.

Latest Ratings for ALGN

DateFirmActionFromTo
Apr 2015Morgan StanleyUpgradesEqual-weightOverweight
Jan 2015JefferiesMaintainsBuy
Jan 2015JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (ALGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters